Inventor · disambiguated record
Jon M. Wigginton
Also filed as: WIGGINTON JON · WIGGINTON JON M · WIGGINTON JON MARC
19 granted patents·18 pending applications·517 citations·filing 2011–2025
97Inventor score
Files withBRISTOL MYERS SQUIBB CO22MACROGENICS INC11CULLINAN PEARL CORP1INCYTE CORP1JURE-KUNKEL MARIA1
Top patents by PatentIndex Score
37 records- 0198US10604575B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 31, 2020·26 cites·17 claims
- 0298US10323092B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·30 cites·26 claims
- 0398US10323093B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 18, 2019·29 cites·18 claims
- 0498US10316091B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·30 cites·26 claims
- 0598US10308714B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 4, 2019·30 cites·27 claims
- 0698US10266595B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·28 cites·30 claims
- 0798US10266594B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0898US10266596B1Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·29 cites·30 claims
- 0998US10138299B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 27, 2018·39 cites·25 claims
- 1098US10072082B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 11, 2018·58 cites·28 claims
- 1198US9856320B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 2, 2018·94 cites·22 claims
- 1297US10584170B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 10, 2020·23 cites·27 claims
- 1397US10577423B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 3, 2020·23 cites·27 claims
- 1497US10316090B2Cancer immunotherapy by disrupting PD-1/PD-L1 signalingBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Jun 11, 2019·29 cites·27 claims
- 1593US9789182B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 17, 2017·11 cites·15 claims
- 1692US2024417471A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 1786US11078279B2Combination therapy for the treatment of cancerMACROGENICS INC·Filed 2016·Granted Aug 3, 2021·5 cites·20 claims
- 1886US2024002512A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 1986US2024034793A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2084US10688180B2Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jun 23, 2020·2 cites·15 claims
- 2179US11174315B2Combination therapy for the treatment of cancerMACROGENICS INC·Filed 2016·Granted Nov 16, 2021·2 cites·39 claims
- 2275US2020308282A1Cancer immunotherapy by disrupting pd-1/pd-l1 signalingBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 2367US2025215088A1Combination therapy for the treatment of cancerTERSESA THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 2464US2022041725A1Combination Therapy for the Treatment of CancerMACROGENICS INC·Filed 2021·Application pending·0 cites
- 2562US2022204625A1Combination Therapy for the Treatment of CancerMACROGENICS INC·Filed 2021·Application pending·0 cites
- 2654US2023372346A1Treatment regimens for exon-20 insertion mutant egfr cancersCULLINAN PEARL CORP·Filed 2021·Application pending·0 cites
- 2754US2023226206A1Methods for the use of a b7-h3 antibody-drug conjugate alone or in combinationMACROGENICS INC·Filed 2021·Application pending·0 cites
- 2852US2023056230A1Therapy for the Treatment of CancerMACROGENICS INC·Filed 2020·Application pending·0 cites
- 2951US2015290316A1Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2013·Application pending·0 cites
- 3049US12448448B2Anti-PD-1 antibodies and uses thereofINCYTE CORP·Filed 2019·Granted Oct 21, 2025·0 cites·6 claims
- 3149US2018099045A1Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancerBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3249US2023312756A1Methods for the use of a pd-1 x ctla-4 bispecific moleculeMACROGENICS INC·Filed 2021·Application pending·0 cites
- 3347US2022213203A1Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic MalignanciesMACROGENICS INC·Filed 2020·Application pending·0 cites
- 3446US2013156768A1Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseasesJURE-KUNKEL MARIA·Filed 2011·Application pending·0 cites
- 3541US2020255524A1Combination therapyMACROGENICS INC·Filed 2017·Application pending·0 cites
- 3639US2019322741A1Methods for the Use of CD32B x CD79B-Binding Molecules in the Treatment of Inflammatory Diseases and DisordersMACROGENICS INC·Filed 2017·Application pending·0 cites
- 3738US2021061911A1Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic MalignanciesMACROGENICS INC·Filed 2017·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →